Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new modeling study shows that antiviral post-exposure prophylaxis (PEP) could cut healthcare worker deaths by up to 80% during Ebola outbreaks — but only when rolled out quickly and at high coverage. Delays and operational disruptions dramatically reduce that benefit. The findings highlight the urgent need for rapid, well-resourced PEP deployment strategies to protect frontline workers.
A modeling study published in The Lancet Infectious Diseases suggests that antiviral post-exposure prophylaxis (PEP) targeted at healthcare workers (HCWs) could dramatically reduce deaths during orthoebolavirus (Ebola) outbreaks — but the window for impact is narrow. When delivered immediately at full coverage, PEP with 80% efficacy cut HCW deaths by 80% in both West Africa-like and DR Congo-like outbreak scenarios. That benefit eroded sharply with delays: a scaled rollout over one year reduced deaths by only ~19–22%.
The study also found that targeting PEP to high-risk exposures — such as PPE breaches or direct fluid contact — was far more dose-efficient than broad allocation, a critical consideration given limited supply in outbreak settings.
By the Numbers:
Why it matters: HCWs are both the most exposed and the most essential resource during Ebola outbreaks. These findings make a strong case for pre-positioning antiviral stockpiles and building rapid-deployment infrastructure well before the next outbreak strikes.
